Fig. 1 · Structure

Documents & Downloads

Indinavir sulfate

Cat. No. A11871 CAS 157810-81-6
Indinavir sulfate is a novel hydroxyaminopentane amide class of HIV-1 protease inhibitors.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
MMP-2  
HIV-1  

Cellular Effect

Cell Line Activity Value Description Reference
C8166 EC50 0.0082 μM Antiviral activity against HIV1 infected human C8166 cells assessed as inhibition of viral replication after 4 days by p24 antigen capture ELISA [PMID: 19618920]
C8166 EC50 5.5 nM Antiviral activity against HIV1 LAI infected in human C8166 cells assessed as inhibition of viral replication by ELISA [PMID: 18855443]
C8166 EC50 8.18 nM Inhibition of HIV1 LAI replication in C8166 cells after 4 days by ELISA [PMID: 18303847]
C8166 EC50 8.71 nM Antiviral activity against HIV-1 M:B_Lai replication in human C8166 cells assessed as inhibition of p24 antigen expression level after 4 days by ELISA [PMID: 19326880]
C8166 EC50 8.81 nM Antiviral activity against HIV1 replication in human C8166 cells by ELISA [PMID: 19101157]
CEM-SS CC50 > 1 x 10 Cytotoxicity against human CEM-SS cells after 5 days by MTT assay [PMID: 17950955]
CEM-SS IC50 ≤ 10 nM Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as reverse transcriptase activity after 5 days by MTT assay [PMID: 17950955]
HepG2 EC50 14.1 μM Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis [PMID: 20966043]
HepG2 EC50 15.8 μM Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis [PMID: 20966043]
MT4 CC50 > 1 x 10 Cytotoxicity against human MT4 cells after 4 days by MTT assay [PMID: 17950955]
MT4 IC50 22 nM Antiviral activity against HTLV1 3B infected in human MT4 cells assessed as reverse transcriptase activity after 5 days by MTT assay [PMID: 17950955]

11 records · Scroll to view more

Indinavir sulfate Research Summary

This section summarizes 4 in vitro studies of Indinavir sulfate from 4 published references. In vitro models include LDM of 3T3-L1 adipocytes; MDMs.

Indinavir sulfate In Vitro Studies

In LDM of 3T3-L1 adipocytes, Indinavir inhibited ATB-BMPA binding, with half-maximal inhibition values of 20.7±3.9 µM for GLUT4 and 178±43 µM for GLUT1. Indinavir did not inhibit cell fusion in co-cultured HL2/3 and HeLa-CD4-LTR-β-gal cells. In MDM co-cultures compared with control media, late Indinavir sulfate addition reduced transmission in each group. In sorted CD11c+ MDC co-cultures, Indinavir addition reduced p24+ T cells after co-culture with HIV-1–infected DCs compared with its absence. [1,2,3,4]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Glucose Transporter Binding in Adipocyte Membranes

Cell-based study · LDM of 3T3-L1 adipocytes [1]

LDM of 3T3-L1 adipocytes were treated with Indinavir. Half-maximal inhibition of ATB-BMPA binding occurred at 20.7±3.9 µM for GLUT4 and 178±43 µM for GLUT1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Half-maximal inhibition (IC50) for ATB-BMPA binding to GLUT4 and GLUT1IC50 GLUT4: 20.7±3.9 µM; GLUT1: 178±43 µM[1]

Literature-Reported Treatment Conditions

Exposure duration
10 min at room temperature
Method
added to 200 µg of LDM
Vehicle
water
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: Indinavir

The paper names Indinavir without stating the salt or form; not verified as the sulfate form supplied as A11871. No dose conversion or lot validation.

Materials and Methods > Materials (S7); Results > Effect of PIs on ATB-BMPA labeling and glucose uptake (S66); Figure 5 legend (S144, S145, S146, S148); Table 1 legend (S153, S156); Table 1 (T1.h1, T1.r1)

Half-maximal inhibition (IC50) for ATB-BMPA binding to GLUT4 and GLUT1: Half-maximal inhibition (IC50) for ATB-BMPA binding to GLUT4 and GLUT1; comparator: vehicle treated controls — Table 1 legend (S153, S156); Table 1 (T1.h1, T1.r1)

Cell Fusion in Co-cultured Cells

Cell-based study · HL2/3 cells; HeLa-CD4-LTR-β-gal cells [2]

Indinavir was evaluated in co-cultured HL2/3 and HeLa-CD4-LTR-β-gal cells. It did not inhibit cell fusion in this cell-based fusion assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of inhibition of HL2/3-HeLa CD4 cell fusionReported result did not inhibit cell fusion in this cell-based fusion assay[2]

Literature-Reported Treatment Conditions

Exposure duration
48 h
Method
co-cultured
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Indinavir

The paper names Indinavir without stating the salt or form; not verified as the sulfate form supplied as A11871. No dose conversion or lot validation.

Results > Inhibition of Env/CD4-mediated membrane fusion (S19); Methods > Cell-based fusion assay (S62, S63, S64)

percentage of inhibition of HL2/3-HeLa CD4 cell fusion: percentage of inhibition of HL2/3-HeLa CD4 cell fusion; comparator: positive control of untreated cells — Results > Inhibition of Env/CD4-mediated membrane fusion (S19); Methods > Cell-based fusion assay (S64)

Transmission in MDM Co-cultures

Cell-based study · MDMs [3]

MDM co-cultures received Indinavir sulfate at 1 μM before CD4+ T cell addition, with control media as the comparator. In each group, late indinavir addition reduced transmission.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
% of total CD3+ cells staining for p24Reported result In each group, late indinavir addition reduced transmission[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
2 hours prior to CD4+ T cell addition on day 7
Method
Co-cultures in some instances were treated
Co-treatment
Other interventions in this design: HIV-1 BaL 3 TCID50/cell; GM-CSF; autologous CD4+ T cells 3 cells/MDM; rhIL-2 5 ng/ml. Compound effect isolated by the comparison: indinavir or control media.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Indinavir sulfate; Compound label in the paper: Indinavir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Siglec-mediated uptake of virions into the VCC enhances trans-infection of T lymphocytes (S137); Materials and methods > Macrophage-T cell trans-infection assay (S227, S229, S230, S232, S233, S234); Fig 9 legend (S301, S304)

% of total CD3+ cells staining for p24: % of total CD3+ cells staining for p24; comparator: control media — Results > Siglec-mediated uptake of virions into the VCC enhances trans-infection of T lymphocytes (S137); Fig 9 legend (S304)

Infection in Dendritic Cell Co-cultures

Cell-based study · Sorted CD11c+ MDCs [4]

Indinavir at 1 μM was added to co-cultures of sorted CD11c+ MDCs and autologous CD4+ T cells. Compared with its absence, Indinavir addition reduced p24+ T cells after co-culture with HIV-1–infected DCs.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
frequency of HIV-1 infection (intracellular p24 staining)Reported result The addition of Indinavir led to a reduction of p24+ T cells after co-culture with HIV-1–infected DCs[4]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
3.5 d
Method
added to the co-cultures
Co-treatment
Other interventions in this design: HIV-1BaL 1 μg p24/ml; SEB 0.2 μg/ml; GM-CSF 2 ng/ml; autologous CFSE-labeled CD4+ T cells. Compound effect isolated by the comparison: absence (A and B) or presence (C and D) of the protease inhibitor Indinavir.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Indinavir

The paper names Indinavir without stating the salt or form; not verified as the sulfate form supplied as A11871. No dose conversion or lot validation.

Results > Differential transfer of HIV-1BaL and HIV-1IIIB from MDCs and PDCs to CD4+ T cells (S42, S44); Materials and Methods > DC isolation (S133); Materials and Methods > HIV-1 infection and stimulation of DCs (S143); Materials and Methods > Isolation and CFSE labeling of CD4+ T cells (S158); Materials and Methods > Co-culture of HIV-1–infected DCs with autologous CD4+ T cells (S165, S167, S168); Materials and Methods > Analysis of a DC-mediated transfer of HIV-1 to antigen-specific T cell...

frequency of HIV-1 infection (intracellular p24 staining): frequency of HIV-1 infection (intracellular p24 staining); comparator: absence (A and B) — Results > Differential transfer of HIV-1BaL and HIV-1IIIB from MDCs and PDCs to CD4+ T cells (S44); Figure 3. legend (S208)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 157810-81-6
Formula C36H47N5O4.H2SO4
Molecular Weight 711.87
Synonyms Crixivan
SMILES
CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5.OS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 97 mg/mL (136.26 mM)
Ethanol <1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Indinavir sulfate Research References

  1. [1] Hresko RC, Hruz PW. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One (2011). PMID: 21966466 DOI: 10.1371/journal.pone.0025237 Source material
  2. [2] Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, et al. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology (2010). PMID: 20145735 DOI: 10.1186/1477-3155-8-1 Source material
  3. [3] Hammonds JE, Beeman N, Ding L, et al. Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1. PLoS Pathog (2017). PMID: 28129379 DOI: 10.1371/journal.ppat.1006181 Source material
  4. [4] Loré K, Smed-Sörensen A, Vasudevan J, et al. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med (2005). PMID: 15967828 DOI: 10.1084/jem.20042413 Source material

Added to your cart

View Cart Checkout
Loading...